Author

Federico Bolognani

THE PHARMACOKINETIC AND PHARMACODYNAMIC RELATIONSHIP BETWEEN APRAGLUTIDE AND CITRULLINE: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERS
THE PHARMACOKINETIC AND PHARMACODYNAMIC RELATIONSHIP BETWEEN APRAGLUTIDE AND CITRULLINE: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERS

Federico Bolognani  et al.

THE LONG-ACTING GLP-2 ANALOG APRAGLUTIDE PROVIDES CLINICAL BENEFIT FOR PATIENTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE AND COLON IN CONTINUITY AT 52 WEEKS
THE LONG-ACTING GLP-2 ANALOG APRAGLUTIDE PROVIDES CLINICAL BENEFIT FOR PATIENTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE AND COLON IN CONTINUITY AT 52 WEEKS

Federico Bolognani  et al.

TRANSFERABILITY OF METABOLIC BALANCE STUDIES IN SHORT BOWEL SYNDROME: ANALYSIS OF DRY MATTER AND ENERGY CONTENTS
TRANSFERABILITY OF METABOLIC BALANCE STUDIES IN SHORT BOWEL SYNDROME: ANALYSIS OF DRY MATTER AND ENERGY CONTENTS

Federico Bolognani  et al.

APRAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IMPROVES WET WEIGHT ABSORPTION IN SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) AND COLON-IN-CONTINUITY (CIC)
APRAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IMPROVES WET WEIGHT ABSORPTION IN SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) AND COLON-IN-CONTINUITY (CIC)

Federico Bolognani  et al.

SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME: AN OPEN-LABEL PHASE 2 METABOLIC BALANCE TRIAL
SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME: AN OPEN-LABEL PHASE 2 METABOLIC BALANCE TRIAL

Federico Bolognani  et al.

SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME INTESTINAL FAILURE: A DOUBLE-BLIND, CROSSOVER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL
SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME INTESTINAL FAILURE: A DOUBLE-BLIND, CROSSOVER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL

Federico Bolognani  et al.

Item 1 - 6 / 6
1